The influence of long-term treatment with cyproterone acetate or a cyproterone acetate-ethinyl oestradiol combination on androgen levels in blood of hirsute women

Frölich, Marijke; Vader, Hum L.; Walma, Sjoukjen T.; Rooy, H. A. M. De

doi:10.1016/0022-4731(80)90313-1

Cited by 15 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reduction may be attributed to the central inhibitory effect of CA or CA + EE2 on gonadotropin secretion [14,23] and, consequently, on the inhibition of ovarian steroid secretion [24], The ovarian contribution to circulating levels of the above-mentioned ste roids in the early follicular phase ranged from 42 to 66%, respectively, for A5P and T. This antigonadotropic effect of CA is in agreement with the observations of Fröhlich et al [12], Sawers et al [13], and Brotherton et al…”

Section: Discussionsupporting

confidence: 81%

“…Similar results have been reported by other authors [ 12,17], while other investigators report that DHA-S levels are also significantly increased in hirsute patients [18]. The slight increase in cortisol and DHA-S plasma levels in 2 of our hirsute patients suggests the existence of even minimal increases in adrenal function [19,20].…”

Section: Discussionsupporting

confidence: 79%

“…The significant reduction in the percentage of suppression by DXM of plasma cortisol and T levels, found in hirsute patients treated with CA + EE2, may be related to the observation of increased corticosteroid-binding globulin and sex hormone-binding globulin levels seen during estrogen treatments [12,13,[25][26][27], The similar findings in the case of A5P and 17P and their reduced basal values in the hirsute patients on CA + EE2 therapy suggest an impaired production of these steroids.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, no evidence of decreased adrenal function has been found either in children with preco cious puberty [9] or in women with idiopathic hirsutism [10] receiving a reversed sequential therapy with CA + ethynyl estradiol (EE2) or in adult males treated with 200 mg/day for 10 days [11]. Furthermore, CA treat ment increases circulating levels of sex hormone-binding globulin [12,13] and corticosteroid-binding globulin [11], Other studies have also evidenced the ability of CA to normalize the circulating androgens such as androstenedione and testosterone, either via the hypothalamus-pituitary axis or decreasing circulating androgen levels [14] through a direct action on steroid-producing cells [15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impaired Pregnenolone Secretion after Combined Cyproterone Acetate and Ethynyl Estradiol Therapy in Hirsute Patients

Inaudi¹,

D'Ambrogio²,

Massafra³

et al. 1982

Gynecol Obstet Invest

View full text Add to dashboard Cite

6 women affected by hirsutism, either of idiopathic origin or due to polycystic ovary syndrome, have been treated with cyproterone acetate and ethynyl estradiol in combined therapy using, respectively, 100 mg and 50 µg/day, from the 5th to the 25th day of the cycle. The adrenal function was assessed before treatment and at the end of the 4th month of therapy, evaluating the peripheral plasma concentrations of pregnenolone (Δ₅P), progesterone, 17-OH-progesterone, dehydro-epiandrosterone sulfate, androstenedione, testosterone, and cortisol in basal conditions and after dexamethasone suppression and an adrenocorticotropic hormone (ACTH) stimulation test. A group of healthy, untreated females were examined in the early follicular phase, as controls. Before therapy, the hirsute patients showed testosterone and androstenedione plasma levels, which were significantly higher than in the controls, and a significant reduction in pregnenolone response to ACTH. After 4 months of therapy with cyproterone acetate plus ethynyl estradiol, a significant decrease was found in testosterone and androstenedione plasma levels, and pregnenolone basal plasma levels, dexamethasone suppressibility, and response to ACTH were also markedly reduced, showing a significant difference versus the same patients before therapy and versus the control group. The existence of an impairment in adrenal function after cyproterone acetate plus ethynyl estradiol therapy at the given dose seems to be evident only in the case of directly ACTH-dependent adrenal enzymatic activities responsible for cholesterol cleavage to pregnenolone.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impaired Pregnenolone Secretion after Combined Cyproterone Acetate and Ethynyl Estradiol Therapy in Hirsute Patients

Inaudi¹,

D'Ambrogio²,

Massafra³

et al. 1982

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Androstenedione is not bound to TeBG, and so the decrease in plasma level is much more marked than the decrease in the total testosterone levels. Previous reports have mentioned similar results (Frohlich et al 1977(Frohlich et al , 1980Kuttenn et al 1980). Dihydrotestosterone levels decreased only slightly.…”

Section: Discussionsupporting

confidence: 73%

Androgen Levels During Cyproterone Acetate and Ethinyl Oestradiol Treatment of Hirsutism

Rubens

1984

Clinical Endocrinology

View full text Add to dashboard Cite

Androgen levels were measured before and during 12 months of treatment with cyproterone acetate (50 mg 5th to 16th day of cycle) and ethinyl oestradiol (50 micrograms 5th to 26th day of cycle) in 26 patients suffering from dysfunctional hirsutism. Patients were included in whom androgen levels after a dexamethasone suppression test fell above the range found in normal non-hirsute women on dexamethasone. Eighty percent of patients showed a substantial improvement of their Ferriman and Gallwey score after 12 months of treatment. During the treatment the mean level of testosterone was 64%, androstenedione 55%, testosterone oestradiol binding globulin 365%, apparent free testosterone 30%, dihydrotestosterone 74%, 5-androstanediol 43%, dehydroepiandrosterone 44%, 5-androstenediol 67% and dehydroepiandrosterone sulphate 74% of basal levels. From the results it is concluded that this treatment is effective both clinically and biochemically in reducing hyperandrogenism.

show abstract

Antiandrogens: Clinical Aspects

Hammerstein¹

1990

Hair and Hair Diseases

View full text Add to dashboard Cite

The influence of long-term treatment with cyproterone acetate or a cyproterone acetate-ethinyl oestradiol combination on androgen levels in blood of hirsute women

Cited by 15 publications

References 13 publications

Impaired Pregnenolone Secretion after Combined Cyproterone Acetate and Ethynyl Estradiol Therapy in Hirsute Patients

Impaired Pregnenolone Secretion after Combined Cyproterone Acetate and Ethynyl Estradiol Therapy in Hirsute Patients

Androgen Levels During Cyproterone Acetate and Ethinyl Oestradiol Treatment of Hirsutism

Antiandrogens: Clinical Aspects

Contact Info

Product

Resources

About